Office of Generic Drugs
The Office of Generic Drugs (OGD) is responsible for providing regulatory oversight to expedite the availability of safe, effective, and high-quality generic drugs to patients. We also provide guidance to regulated industry on a wide variety of clinical, scientific, and regulatory matters relating to generic drugs. We are committed to maintain the public’s confidence in an Agency that continues to meet the ever-changing needs of public health.
To ensure through a scientific and regulatory process, that generic drugs are safe and effective for the American public.
OGD is the interface for abbreviated new drug (ANDA) firms to interact with the Generic Drug Program.
News and Announcements
Activities Report of the Generic Drug Program (FY 2014, updated monthly)
FDA staff presentations can be found on the Meeting Presentations (Drugs) page.